Help get Uptravi to patients!

A new medication for pulmonary arterial hypertension (PAH) UptraviĀ® (selexipag) is undergoing assessment by the Common Drug Review (CDR) CDR reviews clinical, economic, and patient evidence, and uses this information to make recommendations to the majority of Canada's public drug plans on whether or not medications should be funded and with what eligibility criteria. Uptravi, [...]